
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-a68b4900.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-0a3f24ce.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Immune-related adverse events—pembrolizumab-induced colitis—the importance of early diagnosis and treatment: A case report and review of the literature - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="5BB8C7D681CD809307C7D60031EA22A4.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="ijip">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12033556/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="International Journal of Immunopathology and Pharmacology">
<meta name="citation_title" content="Immune-related adverse events—pembrolizumab-induced colitis—the importance of early diagnosis and treatment: A case report and review of the literature">
<meta name="citation_author" content="Marina Markovic">
<meta name="citation_author_institution" content="Center for Internal Oncology, University Clinical Center Kragujevac, Kragujevac, Serbia">
<meta name="citation_author_institution" content="Department of Internal Medicine, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia">
<meta name="citation_author" content="Danijela Niciforovic">
<meta name="citation_author_institution" content="Center for Internal Oncology, University Clinical Center Kragujevac, Kragujevac, Serbia">
<meta name="citation_author" content="Violeta Mladenovic">
<meta name="citation_author_institution" content="Department of Internal Medicine, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia">
<meta name="citation_author_institution" content="Endocrinology Clinic, University Clinical Center Kragujevac, Kragujevac, Serbia">
<meta name="citation_author" content="Dragica Pavlovic">
<meta name="citation_author_institution" content="Department of Genetics, Faculty of Medical Sciences, Center for Harm Reduction of Biological and Chemical Hazards, University of Kragujevac, Kragujevac, Serbia">
<meta name="citation_author" content="Dragana Papic">
<meta name="citation_author_institution" content="Department of Genetics, Faculty of Medical Sciences, Center for Harm Reduction of Biological and Chemical Hazards, University of Kragujevac, Kragujevac, Serbia">
<meta name="citation_author" content="Katarina Milojevic">
<meta name="citation_author_institution" content="Center for Internal Oncology, University Clinical Center Kragujevac, Kragujevac, Serbia">
<meta name="citation_author" content="Dalibor Jovanovic">
<meta name="citation_author_institution" content="Department of Pathology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia">
<meta name="citation_author" content="Marija Spasojevic">
<meta name="citation_author_institution" content="Department of Pathology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia">
<meta name="citation_author_institution" content="Department of Pathological Anatomy, University Clinical Center Kragujevac, Kragujevac, Serbia">
<meta name="citation_author" content="Rade Milic">
<meta name="citation_author_institution" content="Pulmonology Clinic, Military Medical Academy, Belgrade, Serbia">
<meta name="citation_author_institution" content="Medical Faculty, Military Medical Academy, University of Defence, Belgrade, Serbia">
<meta name="citation_publication_date" content="2025 Apr 15">
<meta name="citation_volume" content="39">
<meta name="citation_firstpage" content="03946320251326699">
<meta name="citation_doi" content="10.1177/03946320251326699">
<meta name="citation_pmid" content="40231646">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12033556/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12033556/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12033556/pdf/10.1177_03946320251326699.pdf">
<meta name="description" content="Immune Checkpoint Inhibitors (ICIs) are monoclonal antibodies that block inhibitory immune targets, such as cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1), and programmed death ligand 1 (PD-L). Pembrolizumab ...">
<meta name="og:title" content="Immune-related adverse events—pembrolizumab-induced colitis—the importance of early diagnosis and treatment: A case report and review of the literature">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Immune Checkpoint Inhibitors (ICIs) are monoclonal antibodies that block inhibitory immune targets, such as cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1), and programmed death ligand 1 (PD-L). Pembrolizumab ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12033556/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-testid="header" data-header >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            
                <a class="ncbi-header__logo-container" href="https://www.ncbi.nlm.nih.gov/">
                    <img alt="
                                  NCBI home page
                              "
                         class="ncbi-header__logo-image"
                         src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg" />
                </a>
            

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            


    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true"    >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                


    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true"    >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                


    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true"    data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                


    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true"    data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
    

    Dashboard

    
</a>

                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
    

    Publications

    
</a>

                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
    

    Account settings

    
</a>

                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-testid="searchPanel"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      aria-describedby="search-field-desktop-navigation-help-text"
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only"
                           data-testid="label"
                           for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           data-testid="textInput"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    data-testid="button"
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  role="search">
                <label class="usa-sr-only" for="search-field">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="search" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
    

    Dashboard

    
</a>

                        </li>
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
    

    Publications

    
</a>

                        </li>
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
    

    Account settings

    
</a>

                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        <a class="usa-link" href="https://www.ncbi.nlm.nih.gov/pmc/advanced/" data-ga-action="featured_link" data-ga-label="advanced_search">
                            Advanced Search
                        </a>
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12033556">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1177/03946320251326699"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/10.1177_03946320251326699.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12033556%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12033556/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12033556/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12033556/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-ijip.gif" alt="International Journal of Immunopathology and Pharmacology logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to International Journal of Immunopathology and Pharmacology" title="Link to International Journal of Immunopathology and Pharmacology" shape="default" href="http://journals.sagepub.com/home/iji" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Int J Immunopathol Pharmacol</button></div>. 2025 Apr 15;39:03946320251326699. doi: <a href="https://doi.org/10.1177/03946320251326699" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1177/03946320251326699</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Int%20J%20Immunopathol%20Pharmacol%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Int%20J%20Immunopathol%20Pharmacol%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Int%20J%20Immunopathol%20Pharmacol%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Int%20J%20Immunopathol%20Pharmacol%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Immune-related adverse events—pembrolizumab-induced colitis—the importance of early diagnosis and treatment: A case report and review of the literature</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Markovic%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Marina Markovic</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Marina Markovic</span></h3>
<div class="p">
<sup>1</sup>Center for Internal Oncology, University Clinical Center Kragujevac, Kragujevac, Serbia</div>
<div class="p">
<sup>2</sup>Department of Internal Medicine, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Markovic%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Marina Markovic</span></a>
</div>
</div>
<sup>1,</sup><sup>2,</sup><sup>*</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Niciforovic%20D%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Danijela Niciforovic</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Danijela Niciforovic</span></h3>
<div class="p">
<sup>1</sup>Center for Internal Oncology, University Clinical Center Kragujevac, Kragujevac, Serbia</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Niciforovic%20D%22%5BAuthor%5D" class="usa-link"><span class="name western">Danijela Niciforovic</span></a>
</div>
</div>
<sup>1,</sup><sup>*</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mladenovic%20V%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Violeta Mladenovic</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Violeta Mladenovic</span></h3>
<div class="p">
<sup>2</sup>Department of Internal Medicine, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia</div>
<div class="p">
<sup>3</sup>Endocrinology Clinic, University Clinical Center Kragujevac, Kragujevac, Serbia</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mladenovic%20V%22%5BAuthor%5D" class="usa-link"><span class="name western">Violeta Mladenovic</span></a>
</div>
</div>
<sup>2,</sup><sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Pavlovic%20D%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Dragica Pavlovic</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Dragica Pavlovic</span></h3>
<div class="p">
<sup>4</sup>Department of Genetics, Faculty of Medical Sciences, Center for Harm Reduction of Biological and Chemical Hazards, University of Kragujevac, Kragujevac, Serbia</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Pavlovic%20D%22%5BAuthor%5D" class="usa-link"><span class="name western">Dragica Pavlovic</span></a>
</div>
</div>
<sup>4,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Papic%20D%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Dragana Papic</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Dragana Papic</span></h3>
<div class="p">
<sup>4</sup>Department of Genetics, Faculty of Medical Sciences, Center for Harm Reduction of Biological and Chemical Hazards, University of Kragujevac, Kragujevac, Serbia</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Papic%20D%22%5BAuthor%5D" class="usa-link"><span class="name western">Dragana Papic</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Milojevic%20K%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Katarina Milojevic</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Katarina Milojevic</span></h3>
<div class="p">
<sup>1</sup>Center for Internal Oncology, University Clinical Center Kragujevac, Kragujevac, Serbia</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Milojevic%20K%22%5BAuthor%5D" class="usa-link"><span class="name western">Katarina Milojevic</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Jovanovic%20D%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Dalibor Jovanovic</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Dalibor Jovanovic</span></h3>
<div class="p">
<sup>5</sup>Department of Pathology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Jovanovic%20D%22%5BAuthor%5D" class="usa-link"><span class="name western">Dalibor Jovanovic</span></a>
</div>
</div>
<sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Spasojevic%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Marija Spasojevic</span></a><div hidden="hidden" id="id8">
<h3><span class="name western">Marija Spasojevic</span></h3>
<div class="p">
<sup>5</sup>Department of Pathology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia</div>
<div class="p">
<sup>6</sup>Department of Pathological Anatomy, University Clinical Center Kragujevac, Kragujevac, Serbia</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Spasojevic%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Marija Spasojevic</span></a>
</div>
</div>
<sup>5,</sup><sup>6</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Milic%20R%22%5BAuthor%5D" class="usa-link" aria-describedby="id9"><span class="name western">Rade Milic</span></a><div hidden="hidden" id="id9">
<h3><span class="name western">Rade Milic</span></h3>
<div class="p">
<sup>7</sup>Pulmonology Clinic, Military Medical Academy, Belgrade, Serbia</div>
<div class="p">
<sup>8</sup>Medical Faculty, Military Medical Academy, University of Defence, Belgrade, Serbia</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Milic%20R%22%5BAuthor%5D" class="usa-link"><span class="name western">Rade Milic</span></a>
</div>
</div>
<sup>7,</sup><sup>8</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="aff1-03946320251326699">
<sup>1</sup>Center for Internal Oncology, University Clinical Center Kragujevac, Kragujevac, Serbia</div>
<div id="aff2-03946320251326699">
<sup>2</sup>Department of Internal Medicine, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia</div>
<div id="aff3-03946320251326699">
<sup>3</sup>Endocrinology Clinic, University Clinical Center Kragujevac, Kragujevac, Serbia</div>
<div id="aff4-03946320251326699">
<sup>4</sup>Department of Genetics, Faculty of Medical Sciences, Center for Harm Reduction of Biological and Chemical Hazards, University of Kragujevac, Kragujevac, Serbia</div>
<div id="aff5-03946320251326699">
<sup>5</sup>Department of Pathology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia</div>
<div id="aff6-03946320251326699">
<sup>6</sup>Department of Pathological Anatomy, University Clinical Center Kragujevac, Kragujevac, Serbia</div>
<div id="aff7-03946320251326699">
<sup>7</sup>Pulmonology Clinic, Military Medical Academy, Belgrade, Serbia</div>
<div id="aff8-03946320251326699">
<sup>8</sup>Medical Faculty, Military Medical Academy, University of Defence, Belgrade, Serbia</div>
<div class="author-notes p">
<div class="fn" id="corresp1-03946320251326699">
<sup>✉</sup><p class="display-inline">Dragica Pavlovic, Department of Genetics, Faculty of Medical Sciences, Center for Harm Reduction of Biological and Chemical Hazards, University of Kragujevac, 69 Svetozar Markovic Street, Kragujevac 34000, Serbia. Email: <span>dragica.miloradovic8@gmail.com</span></p>
</div>
<div class="fn" id="corresp2-03946320251326699">
<sup>✉</sup><p class="display-inline">Danijela Niciforovic, Center for Internal Oncology, University Clinical Center Kragujevac, Zmaj Jovina 30, Kragujevac 34000, Serbia. Email: <span>drmed.danijela.niciforovic@gmail.com</span></p>
</div>
<div class="fn" id="fn1-03946320251326699">
<sup>*</sup><p class="display-inline">These authors have contributed equally to this work and share first authorship.</p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2024 Sep 1; Accepted 2025 Feb 24; Collection date 2025 Jan-Dec.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© The Author(s) 2025</div>
<p>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (<a href="https://creativecommons.org/licenses/by-nc/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://creativecommons.org/licenses/by-nc/4.0/</a>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<a href="https://us.sagepub.com/en-us/nam/open-access-at-sage" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://us.sagepub.com/en-us/nam/open-access-at-sage</a>).</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12033556  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40231646/" class="usa-link">40231646</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2>
<p>Immune Checkpoint Inhibitors (ICIs) are monoclonal antibodies that block inhibitory immune targets, such as cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1), and programmed death ligand 1 (PD-L). Pembrolizumab targets the PD-1 receptor of lymphocytes in lung cancer treatment. ICI checkpoint blockade enhances immunity against cancer cells. However, loss of immunoregulatory control can cause autoimmune reactions in various organs, leading to immune-related adverse events (irAEs). The most common irAE is ICIs-induced colitis, which usually develops 6–8 weeks after ICI initiation and can involve any part of the gastrointestinal system. Herein, we report a presentation of pembrolizumab-induced colitis in a female patient with metastatic lung cancer and review the most recent findings in the model of checkpoint-induced colitis. It was interesting to learn that the colon mucosa may show normal macroscopic findings, but microscopically, immunotherapy-induced autoimmune colitis could be present. Additionally, patients with grade 2 or higher symptoms should have a colonoscopy, receive systemic corticosteroids as treatment, and, based on their response, receive biologic therapy. Here, we present a case report of in a 45-year-old female who has been a smoker for 25 years, without comorbidities, and with metastatic lung cancer who developed colitis after the seventh cycle of pembrolizumab. This case presentation highlights the importance of early recognition and appropriate intervention in order to prevent permanent interruption of treatment with checkpoint inhibitors, as well as prevention of colitis complications.</p>
<section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> checkpoint inhibitor induced colitis, immune checkpoint inhibitors, immune-related adverse events, immunotherapy, non-small cell lung carcinoma, pembrolizumab</p></section></section><section id="section1-03946320251326699"><h2 class="pmc_sec_title">Introduction</h2>
<p>Since 2011, the FDA (Food and Drug Administration) has approved several ICIs, including CTLA-4 inhibitors (ipilimumab), PD-L1 inhibitors (atezolizumab, avelumab, and durvalumab), and PD-1 inhibitors (nivolumab and pembrolizumab). These ICIs showed efficacy for many cancers, including advanced-stage melanoma, renal cell carcinoma, triple negative breast cancer (TNBC), gastrointestinal cancers and non-small cell lung carcinoma (NSCLC).<sup>
<a href="#bibr1-03946320251326699" class="usa-link" aria-describedby="bibr1-03946320251326699">1</a>
</sup> Immune checkpoint inhibitors (ICIs) are linked to organ-specific adverse events (AEs), which differ from those associated with conventional chemotherapies and multikinase inhibitors.<sup>
<a href="#bibr2-03946320251326699" class="usa-link" aria-describedby="bibr2-03946320251326699">2</a>
</sup> These adverse events present as autoimmune or inflammatory disease-like reactions and are termed immune-related adverse events (irAEs).<sup>
<a href="#bibr3-03946320251326699" class="usa-link" aria-describedby="bibr3-03946320251326699">3</a>
</sup> IrAEs occur as a result of overstimulation of the immune system by blockade of ICIs. The occurrence of irAEs depends on the tumor type, agent, dose, and patient characteristics. The median of IrAEs is about 40 days and they may be described as “acute” if they develop during treatment, “delayed” if they appear following ICI completion, and “chronic” if they persist beyond 12 weeks after discontinuation of therapy.<sup>
<a href="#bibr4-03946320251326699" class="usa-link" aria-describedby="bibr4-03946320251326699">4</a>
</sup> Any organ system can be affected by IrAEs, therefore iAEs such as pneumonitis, myocarditis, pericarditis, hepatitis, pancreatitis, vasculitis, acute coronary syndrome, myositis and adrenal insufficiency as well as skin toxicities.<sup>
<a href="#bibr5-03946320251326699" class="usa-link" aria-describedby="bibr5-03946320251326699">5</a>
</sup> Additionaly, haematological toxicities, neurological toxicities have been noted so far.<sup>
<a href="#bibr1-03946320251326699" class="usa-link" aria-describedby="bibr1-03946320251326699">1</a>
</sup> One of important IrAEs is colitis which could be one of the leading causes of hospitalization and quality of life deterioration during ICI treatment.<sup>
<a href="#bibr6-03946320251326699" class="usa-link" aria-describedby="bibr6-03946320251326699">6</a>
</sup> Pembrolizumab, a monoclonal humanized anti-PD-1 antibody, is used to treat metastatic NSCLC and other conditions like TNBC, melanoma, and gastrointestinal cancers.<sup>
<a href="#bibr6-03946320251326699" class="usa-link" aria-describedby="bibr6-03946320251326699">6</a>
</sup> Researchers report a higher incidence of ICI-induced colitis with a combination of ICI therapy.<sup>
<a href="#bibr4-03946320251326699" class="usa-link" aria-describedby="bibr4-03946320251326699">4</a>
</sup> The incidence of colitis due to the use of PD-1 inhibitors, in the first place pembrolizumab, is 1.2%–0.2%, and the incidence due to the use of PD-L1 inhibitors is 0.3%–0.004%. Among PD-1 inhibitors, such as pembrolizumab, and PD-L1 inhibitors, the incidence of mild colitis is more frequent using PD-1 than PD-L1 (1.2% vs 0.3%); for severe colitis, there is no significant difference between pembrolizumab and PD-L1 inhibitors.<sup>
<a href="#bibr4-03946320251326699" class="usa-link" aria-describedby="bibr4-03946320251326699">4</a>
</sup> In ICI-induced colitis, CD8+ Tissue Resident Memory T cells (TRM CD8+ cells) differentiate into cytotoxic T lymphocytes (TLy CD8+) that can release interferon-gamma (IFNγ) and Tumor Necrosis Factor—alpha (TNF-α). This damages and inflames the intestinal epithelial barrier.<sup>
<a href="#bibr7-03946320251326699" class="usa-link" aria-describedby="bibr7-03946320251326699">7</a>
</sup> Colonization of the mucous membranes by TLy CD8+ explains why colitis is a common and early adverse event during immunotherapy. The increased concentration of these lymphocytes in the intestinal mucosa could explain the sudden response to the corticosteroid, which induces apoptosis of activated T lymphocytes.<sup>
<a href="#bibr7-03946320251326699" class="usa-link" aria-describedby="bibr7-03946320251326699">7</a>
</sup> Diarrhea/colitis is the most common adverse effect and the most common reason for discontinuing ICI therapy.<sup>
<a href="#bibr8-03946320251326699" class="usa-link" aria-describedby="bibr8-03946320251326699">8</a>
</sup> After the first administration of ICI, the median interval to onset of diarrhea is approximately 4–8 weeks.<sup>
<a href="#bibr8-03946320251326699" class="usa-link" aria-describedby="bibr8-03946320251326699">8</a>
</sup> Some patients experience symptoms as early as 1 week after exposure. Some patients developed symptoms months or even 2 years after discontinuation of the therapy.<sup>
<a href="#bibr8-03946320251326699" class="usa-link" aria-describedby="bibr8-03946320251326699">8</a>
</sup> Clinical presentations are usually non-specific and include fever (46%), hematochezia (64%), abdominal pain (82%), diarrhea (92%), and vomiting.<sup><a href="#bibr8-03946320251326699" class="usa-link" aria-describedby="bibr8-03946320251326699">8</a>,<a href="#bibr9-03946320251326699" class="usa-link" aria-describedby="bibr9-03946320251326699">9</a></sup> Pembrolizumab and others ICIs can cause either mild, moderate, or severe forms of colitis. Some patients could experience rapid progression to serious complications including bowel perforation and even death.<sup><a href="#bibr4-03946320251326699" class="usa-link" aria-describedby="bibr4-03946320251326699">4</a>,<a href="#bibr8-03946320251326699" class="usa-link" aria-describedby="bibr8-03946320251326699">8</a>,<a href="#bibr9-03946320251326699" class="usa-link" aria-describedby="bibr9-03946320251326699">9</a></sup> Experts commonly use the Common Terminology Criteria for Adverse Events, Version 5, to assess and grade the severity of the disease. Grade 1 denotes mild symptoms, while grade 5 signifies the patient’s death due to ICI-induced colitis.<sup>
<a href="#bibr10-03946320251326699" class="usa-link" aria-describedby="bibr10-03946320251326699">10</a>
</sup> Grades 1, 2, and 3 of diarrhea differ in the number of stools: less than four, between four and six, and over seven stools per day (<a href="#table1-03946320251326699" class="usa-link">Table 1</a>). Life-threatening consequences (intestinal ischemia, necrosis, bleeding, toxic megacolon, perforation, and systemic shock) characterize Grade 4, indicating the need for urgent intervention<sup>
<a href="#bibr11-03946320251326699" class="usa-link" aria-describedby="bibr11-03946320251326699">11</a>
</sup> (<a href="#table1-03946320251326699" class="usa-link">Table 1</a>). Once infection, inflammatory bowel disease (IBD) and tumor metastasis are ruled out, Checkpoint Inhibitor Induced Colitis (CIC) can be diagnosed. Before starting treatment, the gold standard for diagnosis is endoscopy with biopsy.<sup><a href="#bibr12-03946320251326699" class="usa-link" aria-describedby="bibr12-03946320251326699">12</a>,<a href="#bibr13-03946320251326699" class="usa-link" aria-describedby="bibr13-03946320251326699">13</a></sup> Endoscopic findings may vary from normal-appearing mucosa to edema and ulcerations. Additionally, endoscopic findings serve as the primary predictors in determining the response of ICI-induced enterocolitis to treatment.<sup>
<a href="#bibr13-03946320251326699" class="usa-link" aria-describedby="bibr13-03946320251326699">13</a>
</sup> Pathohistological patterns of CIC could be classified as follows: acute active colitis, chronic active colitis, microscopic (collagenous and lymphocytic) colitis, graft-versus-host disease-like (GVHD), and other types (mixed type, increased apoptosis, ischemic colitis-like, and non-specific inflammatory reactive changes (NSIRC))<sup>
<a href="#bibr9-03946320251326699" class="usa-link" aria-describedby="bibr9-03946320251326699">9</a>
</sup> (<a href="#table2-03946320251326699" class="usa-link">Table 2</a>).</p>
<section class="tw xbox font-sm" id="table1-03946320251326699"><h3 class="obj_head">Table 1.</h3>
<div class="caption p"><p>Management algorithm for patients with immune-mediated colitis.<sup><a href="#bibr2-03946320251326699" class="usa-link" aria-describedby="bibr2-03946320251326699">2</a>,<a href="#bibr8-03946320251326699" class="usa-link" aria-describedby="bibr8-03946320251326699">8</a>,<a href="#bibr9-03946320251326699" class="usa-link" aria-describedby="bibr9-03946320251326699">9</a>,<a href="#bibr14-03946320251326699" class="usa-link" aria-describedby="bibr14-03946320251326699">14</a></sup>.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
</colgroup>
<thead><tr>
<th align="left" rowspan="1" colspan="1">Grade of colitis (CTCAE)</th>
<th align="left" rowspan="1" colspan="1">Diarrhea</th>
<th align="left" rowspan="1" colspan="1">Other symptoms/signs of colitis</th>
<th align="left" rowspan="1" colspan="1">Evaluation investigations</th>
<th align="left" rowspan="1" colspan="1">Treatment</th>
<th align="left" rowspan="1" colspan="1">ICIs discontinuation</th>
</tr></thead>
<tbody>
<tr>
<td rowspan="1" colspan="1">Grade 1—Mild</td>
<td rowspan="1" colspan="1">&lt; 4_liquid stools/24 h</td>
<td rowspan="1" colspan="1">Feeling well.</td>
<td rowspan="1" colspan="1">– Baseline: CRP, FCP<br>– Stool microscopy for leucocytes, culture, parasites viral PCR, HBPAg, Clostridium difficile toxin, cryptosporidia.</td>
<td rowspan="1" colspan="1">– Anti-motility-agents (atropine, loperamide),<br>– Oral hydration,<br>– Avoid high fiber/lactose diet.</td>
<td rowspan="1" colspan="1">No</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Grade 2—Moderate</td>
<td rowspan="1" colspan="1">4–6_liquid stools/24 h</td>
<td rowspan="1" colspan="1">Abdominal pain, mucus or blood in stool or nausea.</td>
<td rowspan="1" colspan="1">– Baseline tests as above.<br>– Sigmoido/colonoscopy (+/− biopsy).</td>
<td rowspan="1" colspan="1">– Systemic corticosteroids (oral prednisone/intravenous methyl-prednisolone of 1–2 mg/kg/day),<br>– Oral budesonide 9 mg if no bloody diarrhea. The taper of steroids for at least 4–6 weeks.</td>
<td rowspan="1" colspan="1">No</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Grade 3—Severe</td>
<td rowspan="1" colspan="1">⩾ 7_liquid stools/24 h</td>
<td rowspan="1" colspan="1">Severe or persistent abdominal pain, fever, ileus, peritoneal signs.</td>
<td rowspan="1" colspan="1">– Tests as above + Sigmoido/colonoscopy;<br>– Consider CT of abdomen/pelvis,<br>– Abdominal X-ray.</td>
<td rowspan="1" colspan="1">– Intravenous methylprednisolone of 1–2 mg/kg.<br>– Keep electrolyte balance and compensate aggressive fluid.</td>
<td rowspan="1" colspan="1">Yes</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Grade 4—Severe</td>
<td rowspan="1" colspan="1">Life-threatening consequences</td>
<td rowspan="1" colspan="1">Life-threatening consequences</td>
<td rowspan="1" colspan="1">Urgent evaluation and continuous monitoring. Surgery review if bleeding, pain or distension.</td>
<td rowspan="1" colspan="1">Urgent-intervention indicated.</td>
<td rowspan="1" colspan="1">Yes</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Grade 5</td>
<td rowspan="1" colspan="1">Death</td>
<td rowspan="1" colspan="1">Death</td>
<td rowspan="1" colspan="1">Death</td>
<td rowspan="1" colspan="1">Death</td>
<td rowspan="1" colspan="1">Death</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/table1-03946320251326699/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="table-fn1-03946320251326699"><p>CRP: C reactive protein; FCP: fecal calprotectin; PCR: polymerase chain reaction; HBP Ag: helicobacter pylori antigen.</p></div></div></section><section class="tw xbox font-sm" id="table2-03946320251326699"><h3 class="obj_head">Table 2.</h3>
<div class="caption p"><p>Patohistological features and incidence of CIC induced-colitis.<sup><a href="#bibr4-03946320251326699" class="usa-link" aria-describedby="bibr4-03946320251326699">4</a>,<a href="#bibr8-03946320251326699" class="usa-link" aria-describedby="bibr8-03946320251326699">8</a>,<a href="#bibr9-03946320251326699" class="usa-link" aria-describedby="bibr9-03946320251326699">9</a></sup>.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
</colgroup>
<thead><tr>
<th align="left" rowspan="1" colspan="1">Acute active colitis</th>
<th align="left" rowspan="1" colspan="1">Chronic active colitis</th>
<th align="left" colspan="2" rowspan="1">Microscopic 12% of CIC cases</th>
<th align="left" rowspan="1" colspan="1">GVHD</th>
<th align="left" colspan="4" rowspan="1">Other types</th>
</tr></thead>
<tbody>
<tr>
<td rowspan="1" colspan="1">Most frequent</td>
<td rowspan="1" colspan="1">60% of CIC. Also seen in IBD. In recurrent ICI.</td>
<td rowspan="1" colspan="1">Collagenous</td>
<td rowspan="1" colspan="1">Lymphocytic</td>
<td rowspan="1" colspan="1">Less common</td>
<td rowspan="1" colspan="1">Mixed type</td>
<td rowspan="1" colspan="1">Increased apoptosis</td>
<td rowspan="1" colspan="1">Ischemic colitis</td>
<td rowspan="1" colspan="1">NSIRC</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Neutrophilic or eosinophilic infiltrate of LP.</td>
<td rowspan="1" colspan="1">↑ lymphoplasmacytic infiltration in the LP, crypt abscess/cryptitis, Panet cell and crypt metaplasia.</td>
<td rowspan="1" colspan="1">Infrequent subtype of CIC. ↑ intaepithelial Ly-s, thickened subepithelial collagen.</td>
<td rowspan="1" colspan="1">Normal crypt structure, ↑ lymphoplasmacytic inflammation in the LP, intraepithelial lymphocyte infiltration, but no significant acute inflammatory presentation.</td>
<td rowspan="1" colspan="1">Isolated ↑ apoptosis, without active or chronic inflammation, imitating GVHD.</td>
<td rowspan="1" colspan="1">Different patterns overlapping.</td>
<td rowspan="1" colspan="1">Less common.<br>↑ apoptotic cells.</td>
<td rowspan="1" colspan="1">Rare type.<br>Atrophic crypts, re-active epithelial changes, fibrosis in the LP.</td>
<td rowspan="1" colspan="1">↑ lymphoplasmacytic infiltration in the LP, epithelial attenuation, depleted mucin, reactive changes.</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/table2-03946320251326699/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="table-fn2-03946320251326699"><p>LP: lamina propria; Ly-s: lymphocytes; GVHD: Graft-Versus-Host Disease-like.</p></div></div></section><p>It is stated that the use of budesonide formulated to be released specifically in the colon may play a role in the treatment of patients with microscopic ICI-induced colitis.<sup>
<a href="#bibr7-03946320251326699" class="usa-link" aria-describedby="bibr7-03946320251326699">7</a>
</sup></p>
<p>Timely diagnosis and adequate treatment of ICI-induced colitis are crucial for an optimal outcome.<sup>
<a href="#bibr15-03946320251326699" class="usa-link" aria-describedby="bibr15-03946320251326699">15</a>
</sup></p></section><section id="section2-03946320251326699"><h2 class="pmc_sec_title">Global perspective of immune-checkpoint inhibitor toxicity over a decade</h2>
<p>We summarized irAEs from VigiBase, the international pharmacovigilance database, reported from 2008 until January 2023, to characterize trends in irAEs reporting, clinical features, risk factors, and outcomes<sup><a href="#bibr16-03946320251326699" class="usa-link" aria-describedby="bibr16-03946320251326699">16</a>,<a href="#bibr17-03946320251326699" class="usa-link" aria-describedby="bibr17-03946320251326699">17</a></sup> and to update the information previously described by Wang at al.<sup>
<a href="#bibr18-03946320251326699" class="usa-link" aria-describedby="bibr18-03946320251326699">18</a>
</sup></p>
<p>Each case was examined for its administrative data (date, reporter qualifications, and reporting region), patient demographics (sex, age, cancer type), treatment characteristics (immune checkpoint inhibitors and other anticancer medications, prescription indications, initiation and termination dates, administration route), and details of adverse reactions (reported terms, onset and end dates, severity, outcomes including fatalities and progression following drug discontinuation, and any rechallenge).</p></section><section id="section3-03946320251326699"><h2 class="pmc_sec_title">Population</h2>
<p>The most prevalent cancer types associated with irAE were non-small cell lung cancer (15,397/44,589, 34.5%), melanoma (14,630/44,589, 32.8%), and renal cancer (4265/44,589, 9.6%). In 62.4% of patients (31,409/50,347), anti-PD1 or anti-PDL1 monotherapies were administered, while 12.8% (6422/50,347) received anti-CTLA4 + antiPDL1 therapies. A combination of anti-CTLA4 + antiPD(L)1 therapies was included in 16.3% of patients (8215/50,347). The evolution of ICI regimen and cancer categories associated with irAE varied significantly over the four studied time periods of reporting in VigiBase (⩽2016, 2017–2018, 2019–2020, 2021–2022). The proportion of anti-CTLA4 monotherapy-associated irAE almost vanished representing 47% of prescriptions of ICI before 2017 versus 1.6% in 2021–2022 (<em>P</em> &lt; 1 × 10<sup>−160</sup>), in contrast to combination of anti-CTLA4 + anti-PD(L)1 in the same time periods (8.9% vs 20%, <em>P</em> = 2 × 10<sup>−90</sup>).</p></section><section id="section4-03946320251326699"><h2 class="pmc_sec_title">The prevalence of irAE</h2>
<p>In total, 60,323 distinct irAE were identified in 50,347 cases. Skin reactions (22.9%, 11,537/50,347), pneumonitis (18.5%, 9317/50,347), enterocolitis (14.4%), and thyroiditis (12.1%, 6070/50,347) were the most reported irAEs. The proportion of gastro-intestinal irAE (i.e. esogastro-enterocolitis) decreased significantly, representing 23% of total irAE before 2017 compared to 12% in 2021–2022 (<em>P</em> = 7 × 10<sup>−53</sup>). This was in contrast to a significant increase in myotoxicities (i.e. myocarditis, myositis, or myasthenia gravis, 3.7% vs 8.3%, <em>P</em> = 6 × 10<sup>−43</sup>) and pancreatico-hepatic irAE during the same time periods (8.2% vs 11%, <em>P</em> = 6 × 10<sup>−15</sup>).</p></section><section id="section5-03946320251326699"><h2 class="pmc_sec_title">Time to onset and fatality</h2>
<p>The median TTO of irAE from the initiation of ICI therapy was 1–9 months. The median TTO for myotoxicities was the shortest, with a range of 22–60 for myasthenia gravis, 31 days for myositis, and 33 days for myocarditis and 65 days for colitis. Severe cutaneous adverse reactions (SCAR) also had one of the shortest TTOs (40 days, IQR = 14–119). Except for arthritis (104 days, IQR = 31–224), diabetes (114 days, IQR = 45–243), pancreatitis (121 days, IQR = 41–261), esogastritis (126 days, IQR = 45–295), sarcoidosis (141 days, IQR = 75–274), vitiligo (170 days, IQR = 89–326), and skin bullous auto-immune reactions (273 days, IQR = 93–487), the majority of other irAE had a median TTO within 1 and 3 months.</p>
<p>In the narrow irAE population, death occurred in 5709 out of 50,347 individuals, representing 11.3%. The highest overall irAE fatality rates were observed in myocarditis (27.6% and 19.2%, respectively), myasthenia gravis (23.1% and 13.6%), SCAR (22.1% and 12.3%), myositis (21.9% and 11.3%), pneumonitis (21.0% and 10.4%), and encephalomyelitis (18% and 10.9%). The overall reported fatality rates for most life-threatening irAEs decreased over time, with the exception of SCAR and myasthenia gravis which compares rates across the periods ⩽2016, 2017–2018, 2019–2020, and 2021–2022. The overall fatality rates for most other irAEs ranged from 5% to 15%, while the irAE-related fatality rates ranged from 2% to 5%. Arthritis, hypophysitis, diabetes, vitiligo, skin bullous reactions, uveitis, and sarcoidosis exhibited the lowest overall fatality rates (&lt;5%) and very low irAE-related fatality rates (&lt;2%). In the multivariate analysis, myotoxicities, pneumonitis, SCAR, and encephalomyelitis demonstrated a stronger association with overall mortality (OR = 1.7–3.3) relative to other irAE types. In addition to irAE types, factors contributing to increased mortality included age (OR = 1.16, 95% CI = 1.1–1.2 for individuals aged ⩾65 years compared to those aged &lt;65 years), geographic location (eastern Asia versus the rest of the world, OR = 1.9, 95% CI = 1.7–2.0), and specific cancer types, with odds ratios ranging from 1.5 to 2.7 for urothelial, gastro-oesophageal, head and neck, lung, and liver cancers, listed in order of increasing OR. Factors linked to reduced fatality rates included female gender (OR = 0.85, 95% CI = 0.8–0.9 compared to male) and the most recent reporting period (OR = 0.53, 95% CI = 0.5–0.6 for 2017–2022 compared to ⩽2016).</p></section><section id="section6-03946320251326699"><h2 class="pmc_sec_title">Drug discontinuation and rechallenge</h2>
<p>Among the 60,323 identified specific irAE within the 50,347 narrow cases, 27,471 irAE within 23,942 cases had documented outcomes regarding both ICI discontinuation and irAE resolution. A total of 88.1% of irAEs were managed through ICI discontinuation, with 73.9% of cases classified as resolved. The resolution rate for each irAE (in the subset of non-fatal cases) varied between 32.5% and 88.5%. The resolution rate for most irAEs was 70%, with the exceptions of peripheral neuropathy at 65% and vitiligo at 32.5%, which exhibited lower resolution rates. The recurrence rate for specific irAEs, based on 10 available cases, varied between 9.5% and 62.5%. The highest recurrence rates were noted for skin bullous reactions (62.5%), nephritis (36.8%), myocarditis (37.5%), enterocolitis (35.6%), and pneumonitis (32.2%).</p></section><section id="section7-03946320251326699"><h2 class="pmc_sec_title">Gastrointestinal irAEs induced by ICIs</h2>
<p>The latest EudraVigilance and VigiAccess databases indicate that colitis (12,581) and diarrhea (12,108) are the most frequently reported gastrointestinal adverse events.<sup>
<a href="#bibr19-03946320251326699" class="usa-link" aria-describedby="bibr19-03946320251326699">19</a>
</sup> Furthermore, in both databases, the highest number of adverse drug reaction (ADR) reports is linked to nivolumab and pembrolizumab. Durvalumab (ROR: 3.96, 95% CI: 3.65–4.28), ipilimumab (ROR: 1.95, 95% CI: 1.89–2.01), nivolumab (ROR: 1.05, 95% CI: 1.02–1.07), and atezolizumab (ROR: 1.04, 95% CI: 1.01–1.07) exhibited increased risks of gastrointestinal events relative to other immune checkpoint inhibitors. The analysis of EudraVigilance revealed dysphagia, ascites, hematochezia, and gastroesophageal reflux disease as potential signals linked to ICI therapy. A significant proportion of ADR reports (87.2%) consisted of serious gastrointestinal adverse events, with a subset resulting in fatal outcomes (14.5%). Atezolizumab (14.9%), and pembrolizumab (11.9%) demonstrated a greater incidence of fatal outcomes relative to other immune checkpoint inhibitors.</p>
<p>Accordingly, we emphasize the paramount importance of our case report, especially in terms of the need to understand the management of pembrolizumab-induced colitis.</p></section><section id="section8-03946320251326699"><h2 class="pmc_sec_title">Known facts</h2>
<ul id="list1-03946320251326699" class="list" style="list-style-type:disc">
<li><p>Checkpoint inhibitors like pembrolizumab, atezolizumab, and durvalumab have been approved for the treatment of advanced NSCLC in patients whose tumor cells have 50% or higher levels of PD-L1 expression. If tumor cells have PD-L1 protein between 1% and 49%, pembrolizumab and other checkpoint inhibitors are used in combination with chemotherapy to treat NSCLC.<sup>
<a href="#bibr1-03946320251326699" class="usa-link" aria-describedby="bibr1-03946320251326699">1</a>
</sup></p></li>
<li><p>Pembrolizumab can cause immune-related adverse events such as pneumonitis, hepatitis, dermatitis, hypophisitis, pancreatitis, and colitis.<sup>
<a href="#bibr20-03946320251326699" class="usa-link" aria-describedby="bibr20-03946320251326699">20</a>
</sup></p></li>
</ul></section><section id="section9-03946320251326699"><h2 class="pmc_sec_title">A new point of view</h2>
<ul id="list2-03946320251326699" class="list" style="list-style-type:disc">
<li><p>The patterns of ICI reintroduction included the same ICI utilized before, the same type of ICIs, and the switching of ICIs of distinct types. The safety and efficacy of rechallenging ICIs in NSCLC patients, as reported in previous studies. They discovered that switching ICI class therapy produced a superior outcome, with over 50% of patients experiencing stable or partial regression disease.<sup>
<a href="#bibr21-03946320251326699" class="usa-link" aria-describedby="bibr21-03946320251326699">21</a>
</sup></p></li>
<li><p>Gobbini et al.<sup>
<a href="#bibr22-03946320251326699" class="usa-link" aria-describedby="bibr22-03946320251326699">22</a>
</sup> demonstrated that NSCLC patients discontinuing for irAEs had more prolonged survival than those discontinuing for disease progression.</p></li>
<li><p>ICI-induced colitis is an exclusion diagnosis. Corticosteroids are the current first-line treatment, followed by infliximab for steroid-refractory colitis. Vedolizumab and fecal microbiota transplantation are promising options for treatment-refractory ICI-induced colitis.<sup>
<a href="#bibr8-03946320251326699" class="usa-link" aria-describedby="bibr8-03946320251326699">8</a>
</sup></p></li>
</ul></section><section id="section10-03946320251326699"><h2 class="pmc_sec_title">Biological agents (IFX and vedolizumab) in the treatment of refractory microscopic colitis induced by ICIs</h2>
<p>The corticosteroid response for grade 2–4 toxicity should be evaluated early in the treatment of immune-mediated colitis, after 2–3 days. Escalation to a biological agent is recommended for non-responders in the absence of peritonitis, hepatitis, or perforation (infliximab (IFX) 5 mg/kg). Researchers have confirmed that IFX, a TNF-α antagonist, significantly enhances tumor immunity and mitigates resistance to PD-1 inhibitors.<sup>
<a href="#bibr23-03946320251326699" class="usa-link" aria-describedby="bibr23-03946320251326699">23</a>
</sup> In instances where IFX is either ineffective or contraindicated, vedolizumab may be employed. Vedolizumab, an antagonist of a4b7 on CD4 + T cells, prevents T cells from aggregating and returning to the inflammatory intestinal mucosa. 300 mg infusions are administered to treat steroid-refractory cases at 0, 2, and 6 weeks, or until laboratory or clinical improvement.<sup>
<a href="#bibr9-03946320251326699" class="usa-link" aria-describedby="bibr9-03946320251326699">9</a>
</sup> Vedolizumab also induces a response in CIC patients with microscopic colitis confirmed by histopathology. The potential risk of tumor progression in patients with lymph node metastasis may be mitigated by the gastrointestinal selectivity of vedolizumab.<sup>
<a href="#bibr9-03946320251326699" class="usa-link" aria-describedby="bibr9-03946320251326699">9</a>
</sup> In addition, the risk of secondary tumors in susceptible individuals was not elevated by the use of vedolizumab, which possesses the same potential as IFX. Abu-Sbeih et al.<sup>
<a href="#bibr24-03946320251326699" class="usa-link" aria-describedby="bibr24-03946320251326699">24</a>
</sup> discovered that over half of the 179 CIC patients who received IFX or vedolizumab experienced a significantly lower hospitalization, shorter symptom duration, shorter steroid taper/taper attempt, a higher success rate of steroid taper, decreased fecal calprotectin levels, a promoted histological regression rate, and a decreased risk of infection.</p>
<section id="section11-03946320251326699"><h3 class="pmc_sec_title">Gastrointestinal microbiota as an important factor in the development of ICI-induced colitis</h3>
<p>The development of CIC and the response of tumors to ICI therapy may be associated with gut microbiome characteristics. In ICI-induced colitis, the microbiota diversity was significantly reduced, particularly in certain genera within the <em>Firmicutes phylum</em>, such as <em>Faecalibacterium prausnitzii</em> (<em>F.</em> <em>prausnitzii</em>) and <em>Bacteroides fragilis</em> (<em>B.</em> <em>fragilis</em>). The presence of colitis may be linked to the enrichment of <em>F.</em> <em>prausnitzii. F.</em> <em>prausnitzii’s</em> typical function is to maintain the integrity of the colonic mucosa as an obligate anaerobe.<sup>
<a href="#bibr9-03946320251326699" class="usa-link" aria-describedby="bibr9-03946320251326699">9</a>
</sup> The recruitment of Tregs and a4b7 T cells was facilitated by the increase of <em>F.</em> <em>prausnitzii</em>, which was associated with T-cell proliferation in the gastrointestinal mucosa. Furthermore, it has the potential to increase the concentration of CTLs in the tumor microenvironment, thereby extending the progression-free survival (PFS) and overall survive (OS). The protective factor of CIC is the increase in <em>Fragilis</em>. It functions as an anti-inflammatory agent in the gastrointestinal tract.<sup>
<a href="#bibr9-03946320251326699" class="usa-link" aria-describedby="bibr9-03946320251326699">9</a>
</sup> Similar experiments conducted with PD-L1 inhibitors demonstrated that <em>Bifidobacterium species</em> could mediate antitumor efficacy.<sup>
<a href="#bibr25-03946320251326699" class="usa-link" aria-describedby="bibr25-03946320251326699">25</a>
</sup> This bacterium has the potential to reduce gastrointestinal inflammation that is induced by Tregs without compromising the antitumor response.<sup>
<a href="#bibr25-03946320251326699" class="usa-link" aria-describedby="bibr25-03946320251326699">25</a>
</sup> Consequently, the development of CIC may be influenced by the species and relative abundance of intestinal microbiota. The inflammation initiation may be orchestrated by certain microbial species, while other subsets may contribute to the perpetuation of CIC. Additional efforts should be made to further understand the intricate symbiosis between bacteria and ICI-induced colitis, with the ultimate objective of manipulating the microbiota to achieve a balance between the tumor response and irAEs. It is hypothesized that the intestinal microbiome is a critical factor in the development of CIC. Numerous gut microbiomes are associated with the induction or alleviation of ICI-induced colitis. Fecal transplantation has been suggested as an optional therapeutic approach for patients with severe or refractory CIC, as it contributes to the reconstitution of the gut microbiome and the relative increase of regulatory T cells within the colon mucosas.<sup><a href="#bibr4-03946320251326699" class="usa-link" aria-describedby="bibr4-03946320251326699">4</a>,<a href="#bibr8-03946320251326699" class="usa-link" aria-describedby="bibr8-03946320251326699">8</a>,<a href="#bibr9-03946320251326699" class="usa-link" aria-describedby="bibr9-03946320251326699">9</a></sup></p></section></section><section id="section12-03946320251326699"><h2 class="pmc_sec_title">Patients with IBD and risk from development of ICI-induced colitis</h2>
<p>In comparison to non-IBD patients, patients with IBD (Crohn’s disease and ulcerative colitis) are at an elevated risk for GI irAEs. However, these events can be controlled, and these patients necessitate appropriate monitoring. The median time to exacerbation that necessitated corticosteroids in a recently published case series of 13 IBD patients was 5 months following the initiation of the ICI. In a retrospective study, the effects of ICIs on tumor response were consistent between patients with and without IBD.<sup>
<a href="#bibr26-03946320251326699" class="usa-link" aria-describedby="bibr26-03946320251326699">26</a>
</sup></p>
<section id="section13-03946320251326699"><h3 class="pmc_sec_title">Case presentation</h3>
<p>Here, we describe a female patient with metastatic lung cancer who developed colitis after the seventh cycle of pembrolizumab. The patient did not suffer from IBD and it was exclusion criteria in this case.</p></section><section id="section14-03946320251326699"><h3 class="pmc_sec_title">Case description</h3>
<p>In August 2023, a 45-year-old female presented to us with metastatic lung cancer. The first complaints in the form of frequent headaches, forgetfulness, and uncontrollable hand tremors appeared in July 2023. The patient had Eastern Cooperative Oncology Group Performans Status 1 (ECOG PS 1). She has been a smoker for 25 years, averaging 20 cigarettes a day, without comorbidities. The patient`s family history was positive for malignancy (her mother suffered from lung and cervical cancer). We performed an Magnetic resonance imaging (MRI) of the endocranium to establish a diagnosis. MRI of the endocranium (07/23) has shown an expansive frontal lesion in diameter of 3.9 × 3.4 × 3.8 cm, bordered by extensive perifocal vasogenic edema with a compressive effect on the surrounding brain parenchyma, and a smaller cerebellar lesion on the left hemisphere of the brain (<a href="#fig1-03946320251326699" class="usa-link">Figure 1</a>). On the initial Multislice Computed Tomography (MSCT) of the chest (08/23), a spiculated tumor of 28 × 31 × 29 mm was described (on the left at the level of the anterior segment of the upper lobe, posteriorly along the aorta, left a pulmonalis, and along the incision). Mediastinal lymphadenopathy was also described as draining lymph nodes, the largest diameter of which is about 25 × 16 mm (<a href="#fig2-03946320251326699" class="usa-link">Figure 2</a>). According to the eighth world TNM classification, the tumor belongs to T4N2M1, and it is staged as the 4th clinical stage. Operation of the tumor was performed in the area of the frontal region on the left hemisphere of the brain. The tumor on the left in the area of the cerebellum was treated with the X-knife.</p>
<figure class="fig xbox font-sm" id="fig1-03946320251326699"><h4 class="obj_head">Figure 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12033556_10.1177_03946320251326699-fig1.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b10/12033556/83d662bc9723/10.1177_03946320251326699-fig1.jpg" loading="lazy" height="297" width="764" alt="Figure 1."></a></p>
<div class="p text-right font-secondary"><a href="figure/fig1-03946320251326699/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>MRI of endocranium (07/23). The first and second MRI images of this figure depict an expansive frontal lesion with a diameter of 3.9 × 3.4 × 3.8 cm, surrounded by extensive perifocal vasogenic edema that exerts a compressive effect on the surrounding brain parenchyma. The third MRI image of this figure depicts a smaller cerebellar lesion on the left hemisphere of the brain.</p></figcaption></figure><figure class="fig xbox font-sm" id="fig2-03946320251326699"><h4 class="obj_head">Figure 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b10/12033556/ae9d10d90697/10.1177_03946320251326699-fig2.jpg" loading="lazy" height="358" width="607" alt="Figure 2."></p>
<div class="p text-right font-secondary"><a href="figure/fig2-03946320251326699/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>The initial MSCT of the chest (08/23) described a spiculated tumor of 28 × 31 × 29 mm on the left at the level of the anterior segment of the upper lobe.</p></figcaption></figure></section><section id="section15-03946320251326699"><h3 class="pmc_sec_title">The tumor biology</h3>
<p>Pathohistological analysis of brain metastasis revealed primary lung adenocarcinoma.</p>
<p>Molecular testing:</p>
<ul id="list3-03946320251326699" class="list" style="list-style-type:none">
<li><p>– PD-L1—TPS (Tumor Proportion Score) 55%</p></li>
<li><p>–  Anaplastic Lymphoma Kinase (ALK) expression—absent</p></li>
<li><p>–  Epidermal Growth Factor Receptor (EGFR)—no changes were detected in the EGFR gene; wild type EGFR (wtEGFR gene).</p></li>
</ul>
<p>A PD-L expression of more than 50% prompted the start of pembrolizumab treatment. Following four cycles of pembrolizumab, we conducted the first evaluation of the disease. Follow-up MSCT of the chest and abdomen (10/23) showed the first immune unconfirmed progressive disease (iUPD) (in the upper left lobe, the tumor had dimensions of 32 × 68 × 70 mm; Lymph Nodes (LNs) conglomerate from group 4L and 5 measured 37 × 45 × 40 mm; pericardial effusion was 14 mm; <a href="#fig3-03946320251326699" class="usa-link">Figure 3a</a>). Endocranial MRI (10/23) showed stable disease (SD). We performed another control scan after the seventh cycle of pemrolizumab. The MSCT of the chest and abdomen (01/24) revealed immune Stabile Disease (iSD), with the tumor in the upper left lobe measuring 51 × 33 × 60 mm, the LNs conglomerate from group 5 measuring 36 × 30 mm, and the LNs from group 4L measuring 11 mm, all without pericardial and pleural effusion (<a href="#fig3-03946320251326699" class="usa-link">Figure 3b</a>).</p>
<figure class="fig xbox font-sm" id="fig3-03946320251326699"><h4 class="obj_head">Figure 3.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12033556_10.1177_03946320251326699-fig3.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b10/12033556/ce62c202b75a/10.1177_03946320251326699-fig3.jpg" loading="lazy" height="202" width="762" alt="Figure 3."></a></p>
<div class="p text-right font-secondary"><a href="figure/fig3-03946320251326699/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>MSCT of the chest and abdomen. (a) On the left figure of the computed tomography (CT) scan (10/23) is shown iUPD (in the upper left lobe, the tumor had dimensions of 32 × 68 × 70 mm; LNs conglomerate from group 4L and 5 measured 37 × 45 × 40 mm; pericardial effusion was 14 mm). (b) On the right figure of the CT scan (01/24) is shown iSD with the tumor in the upper left lobe measuring 51 × 33 × 60 mm.</p></figcaption></figure><p>After the 7th cycle of pembrolizumab, due to persistent diarrhea, laboratory analyses were performed, as well as stool analysis (<a href="#table3-03946320251326699" class="usa-link">Table 3</a>). Among the complaints, the patient mentioned six loose stools per day, malaise, and a depressed mood phase. The planned eighth cycle of immunotherapy was postponed.</p>
<section class="tw xbox font-sm" id="table3-03946320251326699"><h4 class="obj_head">Table 3.</h4>
<div class="caption p"><p>Laboratory and stool analyses.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
</colgroup>
<thead><tr>
<th align="left" rowspan="1" colspan="1">CBA BMI</th>
<th align="left" rowspan="1" colspan="1">Biochemical analysis</th>
<th align="left" rowspan="1" colspan="1">ICH</th>
<th align="left" rowspan="1" colspan="1">Immunology</th>
<th align="left" rowspan="1" colspan="1">Stool analysis</th>
</tr></thead>
<tbody><tr>
<td rowspan="1" colspan="1">Normal</td>
<td rowspan="1" colspan="1">Normal, except:<br>– Potassium 2.2. . .2.60 mmol/L,<br>– Calcium 2. . .1.97 mmol/L,<br>– Sodium 139. . .133 mmol/L.</td>
<td rowspan="1" colspan="1">Normal:<br>– TSH 1.233 (mlU/L),<br>– FT4 7.7 (pmol/L).</td>
<td rowspan="1" colspan="1">Normal:<br>– IgA 2.46 g/L,<br>– IgG 7.54 g/L,<br>– IgM 0.56 g/L,<br>– C3 0.75 g/L,<br>– C4 0.17 g/L,<br>– RF 4 IU/ml,<br>– ANA DETECT 0.5 (Index).</td>
<td rowspan="1" colspan="1">– Coproculture—without pathogens present,<br>– Clostridium difficile—negative,<br>– Helicobacter Pylori Antigen—negative,<br>– Adeno, Rota, Noro, and Astro viruses—negative,<br>– Candida—negative,<br>– Parasites and eggs—negative.</td>
</tr></tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/table3-03946320251326699/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="table-fn3-03946320251326699"><p>Ig: immunoglobulin; C3 and C4: complement component 3 and 4; TSH: thyroid-stimulating hormone; FT4: thyroxine; RF: rheumatoid factor; ANA: antinuclear antibody.</p></div></div></section><p>The patient was admitted to the Center for Internal Oncology’s chemotherapy department at the beginning of March 2024 to confirm the diagnosis of suspected autoimmune colitis caused by pembrolizumab.</p></section><section id="section16-03946320251326699"><h3 class="pmc_sec_title">Colonoscopy and macroscopic finding of the colon mucosa</h3>
<p>During the hospital stay, a colonoscopy revealed a normal macroscopic finding of the colon mucosa (<a href="#fig4-03946320251326699" class="usa-link">Figure 4</a>). We took polytopic biopsies of the colon.</p>
<figure class="fig xbox font-sm" id="fig4-03946320251326699"><h4 class="obj_head">Figure 4.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12033556_10.1177_03946320251326699-fig4.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b10/12033556/b8d9ad78011b/10.1177_03946320251326699-fig4.jpg" loading="lazy" height="315" width="764" alt="Figure 4."></a></p>
<div class="p text-right font-secondary"><a href="figure/fig4-03946320251326699/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Colonoscopy, demonstrating a normal macroscopic finding of the colon mucosa.</p></figcaption></figure></section><section id="section17-03946320251326699"><h3 class="pmc_sec_title">Pathohistological analysis of the colon mucosa</h3>
<p>The colon’s mucosa, which covered the epithelium and superficial parts, remained intact, showing no histological signs of cryptitis or crypt abscesses. The stroma was swollen and filled with a mild to moderate inflammatory infiltrate made up of lymphocytes, plasma cells, and a few eosinophilic granulocytes. We concluded with a diagnosis of mild to moderate colitis interstitialis—autoimmune (<a href="#fig5-03946320251326699" class="usa-link">Figure 5</a>).</p>
<figure class="fig xbox font-sm" id="fig5-03946320251326699"><h4 class="obj_head">Figure 5.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12033556_10.1177_03946320251326699-fig5.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b10/12033556/1c820cc42e91/10.1177_03946320251326699-fig5.jpg" loading="lazy" height="196" width="764" alt="Figure 5."></a></p>
<div class="p text-right font-secondary"><a href="figure/fig5-03946320251326699/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Microscopic colitis interstitialis (autoimmune), mild to moderate degree: the colon’s mucosa remains intact, a mild-to-moderate diffuse inflammatory infiltrate, consisting of lymphocytes, plasma cells, and rare eosinophilic granulocytes, permeates the edematous stroma. Original magnification: (a) ×40, (b) ×100, and (c) ×200.</p></figcaption></figure></section></section><section id="section18-03946320251326699"><h2 class="pmc_sec_title">Treatment</h2>
<p>In the treatment of our patient, we are guided by European Society for Medical Oncology (ESMO) recommendations. As our patient has grade 2 diarrhea, treatment involves the use of corticosteroid therapy such as prednisolone at a dose of 1 mg/kg. The patient received parenteral corticosteroid therapy (amp. Dexamethasone N0II/12h), potassium supplementation, infusion solutions, probiotic therapy, Loperamide tbl per the scheme, and proton pump blockers (PPI) at the time of hospitalization. A few days after applying the parenteral corticosteroid therapy, the diarrhea subsided. The patient’s clinical symptoms improved, leading to a switch to corticosteroids (Prednisolone) for 4 weeks, followed by a gradual taper and PPI during corticosteroid therapy. The patient is currently free of complaints, has normal laboratory and clinical findings, and continues treatment with pembrolizumab. The last follow-up scan described the disease as stable.</p></section><section id="section19-03946320251326699"><h2 class="pmc_sec_title">Discussion</h2>
<p>ICIs can cause either mild, moderate, or severe forms of colitis.<sup>
<a href="#bibr13-03946320251326699" class="usa-link" aria-describedby="bibr13-03946320251326699">13</a>
</sup> Our patient developed grade 2 colitis with 4–6 liquid stools per day, after the seventh cycle of Pembrolizumab. We made the diagnosis of CIC by ruling out infection, IBD, and tumor metastasis. Stool analysis for various infectious agents was negative. There were no significant deviations in the blood tests except for hypokalemia. The results of immunological and immunochemical analyses, as well as biohumoral markers of inflammation, were within the acceptable range. Endoscopy with biopsy is the gold standard for diagnosis, and microscopically, the acute colitis pattern of injury is the most common finding.<sup>
<a href="#bibr26-03946320251326699" class="usa-link" aria-describedby="bibr26-03946320251326699">26</a>
</sup> The macroscopic examination of our patient’s colonoscopy was normal. Pathistological analysis of polytopic biopsies of the colon confirmed that the condition was a mild to moderate case of microscopic interstitialis, also known as autoimmune colitis. For grade 2 diarrhea or colitis, systemic corticosteroids (prednisone or intravenous methylprednisolone of 1–2 mg/kg/day) should be initiated until the symptom improves to grade 1 or less. After that, the gradual tapering of steroids is recommended for at least 4–6 weeks.<sup><a href="#bibr2-03946320251326699" class="usa-link" aria-describedby="bibr2-03946320251326699">2</a>,<a href="#bibr8-03946320251326699" class="usa-link" aria-describedby="bibr8-03946320251326699">8</a>,<a href="#bibr9-03946320251326699" class="usa-link" aria-describedby="bibr9-03946320251326699">9</a></sup> In the treatment of our patient, we are guided by ESMO recommendations. Our patient had grade 2 diarrhea with 4–6 liquid stools per day, so treatment involved the use of corticosteroid therapy such as prednisolone at a dose of 1 mg/kg. During the patient’s hospitalization, we administered parenteral corticosteroid therapy (amp. Dexamethasone N0II/12h), along with potassium supplementation, infusion solutions, probiotic therapy, Loperamide tbl as per the scheme, and proton pump blockers (PPI). A few days after applying the parenteral corticosteroid therapy, the diarrhea subsided. Due to the improvement of clinical symptoms, the patient was treated with gradual tapering of steroids per os for at least 4–6 weeks with PPI all the time corticosteroid therapy. The patient is currently free of complaints, has normal laboratory and clinical findings, and continues treatment with the 15th cycle of pembrolizumab. The latest multi-slice chest scan has shown immunostable disease (iSD). Some retrospective studies reported that patients who developed ICI-induced diarrhea or colitis had a superior OS than those without gastrointestinal toxicity,<sup>
<a href="#bibr22-03946320251326699" class="usa-link" aria-describedby="bibr22-03946320251326699">22</a>
</sup> as it happened in our case. Early diagnosis and appropriate treatment of ICI-induced colitis is crucial for an optimal result.</p></section><section id="section20-03946320251326699"><h2 class="pmc_sec_title">Conclusion</h2>
<p>Endoscopic findings are the most important factor in predicting how ICI-induced colitis will respond to treatment. Macroscopic findings of the colon mucosa may be normal, but microscopically, it may be autoimmune colitis caused by immunotherapy. Good cooperation between oncologists, gastroenterologists and pathologists is necessary in order to provide timely and adequate treatment of ICI-induced colitis. It is important to note that patients who developed ICI-induced diarrhea/colitis had a superior OS than those without gastrointestinal toxicity. The most important and effective approach to managing adverse events of immunotherapy treatment is early recognition and intervention in order to prevent complications of immune related colitis and prevention of permanent interruption of treatment with Immune check point inhibitors. Vedolizumab and fecal microbiota transplantation are promising options for treatment-refractory ICI-induced colitis.</p></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm">
<div class="fn p" id="fn5"><p><strong>Author contributions:</strong> Marina Markovic: Conceptualization; supervision; Writing – original draft; Writing – review &amp; editing. Danijela Niciforovic: Conceptualization; visualization; Writing – original draft; Writing – review &amp; editing. Violeta Mladenovic: Conceptualization; visualization; Writing – original draft; Writing – review &amp; editing. Dragica Pavlovic: Conceptualization; visualization; Writing – original draft; Writing – review &amp; editing. Dragana Papic: Conceptualization; visualization; Writing – original draft; Writing – review &amp; editing. Katarina Milojevic; visualization; Writing – original draft; help in providing case for MRI and MSCT images. Dalibor Jovanovic: visualization; Writing – original draft; provided case for microscopic images. Marija Spasojevic: visualization; Writing – original draft; provided case for microscopic images. Rade Milic: visualization; Writing – original draft.</p></div>
<div class="fn p" id="fn6"><p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p></div>
<div class="fn p" id="fn7"><p><strong>Funding:</strong> The author(s) received no financial support for the research, authorship, and/or publication of this article.</p></div>
<div class="fn p" id="fn8"><p><strong>Ethicals approval:</strong> Ethical approval was not sought for the present study because *REASON*. Our institution does not require ethical approval for reporting individual cases or case series.</p></div>
<div class="fn p" id="fn9"><p><strong>Informed consent:</strong> Written informed consent was obtained from all subjects before the study.</p></div>
<div class="fn p" id="fn10"><p><strong>Consent to participate:</strong> The patient’s written consent was obtained for the participation in the study.</p></div>
<div class="fn p" id="fn11"><p><strong>Consent for publication:</strong> The patient’s written consent was obtained for the writing and publication of the case, including the publication of images.</p></div>
<div class="fn p" id="fn12">
<p><strong>ORCID iDs:</strong> Danijela Niciforovic <img class="inline" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b10/12033556/46930142c87a/10.1177_03946320251326699-img1.jpg" loading="lazy" alt="Inline graphic">
<a href="https://orcid.org/0009-0001-6123-456X" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://orcid.org/0009-0001-6123-456X</a></p>
<p>Dragica Pavlovic <img class="inline" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b10/12033556/46930142c87a/10.1177_03946320251326699-img1.jpg" loading="lazy" alt="Inline graphic">
<a href="https://orcid.org/0000-0002-7474-7495" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://orcid.org/0000-0002-7474-7495</a></p>
<p>Rade Milic <img class="inline" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b10/12033556/46930142c87a/10.1177_03946320251326699-img1.jpg" loading="lazy" alt="Inline graphic">
<a href="https://orcid.org/0000-0002-6770-6820" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://orcid.org/0000-0002-6770-6820</a></p>
</div>
</div></section><section id="ref-list1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="ref-list1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="bibr1-03946320251326699">
<span class="label">1.</span><cite>
Lugowska I, Misale S, Califano R, et al.  (2022) ESMO Handbook of Targeted Therapies and Precision. Brussels: ESMO Press, vol. 10, pp.124–125.</cite> [<a href="https://scholar.google.com/scholar_lookup?title=ESMO%20Handbook%20of%20Targeted%20Therapies%20and%20Precision&amp;author=I%20Lugowska&amp;author=S%20Misale&amp;author=R%20Califano&amp;publication_year=2022&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr2-03946320251326699">
<span class="label">2.</span><cite>
Baxi S, Yang A, Gennarelli RL, et al.  (2018) Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: Systematic review and meta-analysis. British Medical Journal
360: k793.</cite> [<a href="https://doi.org/10.1136/bmj.k793" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5851471/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29540345/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=British%20Medical%20Journal&amp;title=Immune-related%20adverse%20events%20for%20anti-PD-1%20and%20anti-PD-L1%20drugs:%20Systematic%20review%20and%20meta-analysis&amp;author=S%20Baxi&amp;author=A%20Yang&amp;author=RL%20Gennarelli&amp;volume=360&amp;publication_year=2018&amp;pmid=29540345&amp;doi=10.1136/bmj.k793&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr3-03946320251326699">
<span class="label">3.</span><cite>
Martins F, Sofiya L, Sykiotis GP, et al.  (2019) Adverse effects of immune-checkpoint inhibitors: Epidemiology, management and surveillance. Nature Reviews Clinical Oncology
16: 563–580.</cite> [<a href="https://doi.org/10.1038/s41571-019-0218-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31092901/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Reviews%20Clinical%20Oncology&amp;title=Adverse%20effects%20of%20immune-checkpoint%20inhibitors:%20Epidemiology,%20management%20and%20surveillance&amp;author=F%20Martins&amp;author=L%20Sofiya&amp;author=GP%20Sykiotis&amp;volume=16&amp;publication_year=2019&amp;pages=563-580&amp;pmid=31092901&amp;doi=10.1038/s41571-019-0218-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr4-03946320251326699">
<span class="label">4.</span><cite>
Losurdo G, Angelillo D, Favia N, et al.  (2023) Checkpoint inhibitor-induced colitis: An update. Biomedicines
11: 1496.
</cite> [<a href="https://doi.org/10.3390/biomedicines11051496" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10216810/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37239166/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biomedicines&amp;title=Checkpoint%20inhibitor-induced%20colitis:%20An%20update&amp;author=G%20Losurdo&amp;author=D%20Angelillo&amp;author=N%20Favia&amp;volume=11&amp;publication_year=2023&amp;pages=1496&amp;pmid=37239166&amp;doi=10.3390/biomedicines11051496&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr5-03946320251326699">
<span class="label">5.</span><cite>
Schneider BJ, Naidoo J, Santomasso BD, et al.  (2021) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. Journal of Clinical Oncology
39: 4073–4126.
</cite> [<a href="https://doi.org/10.1200/JCO.21.01440" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34724392/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Clinical%20Oncology&amp;title=Management%20of%20immune-related%20adverse%20events%20in%20patients%20treated%20with%20immune%20checkpoint%20inhibitor%20therapy:%20ASCO%20guideline%20update&amp;author=BJ%20Schneider&amp;author=J%20Naidoo&amp;author=BD%20Santomasso&amp;volume=39&amp;publication_year=2021&amp;pages=4073-4126&amp;pmid=34724392&amp;doi=10.1200/JCO.21.01440&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr6-03946320251326699">
<span class="label">6.</span><cite>
Haanen J, Obeid M, Spain L, et al.  (2022) Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. ESMO Annals of Oncology
33: 1224–1225.</cite> [<a href="https://doi.org/10.1016/j.annonc.2022.10.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36270461/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=ESMO%20Annals%20of%20Oncology&amp;title=Management%20of%20toxicities%20from%20immunotherapy:%20ESMO%20clinical%20practice%20guideline%20for%20diagnosis,%20treatment%20and%20follow-up&amp;author=J%20Haanen&amp;author=M%20Obeid&amp;author=L%20Spain&amp;volume=33&amp;publication_year=2022&amp;pages=1224-1225&amp;pmid=36270461&amp;doi=10.1016/j.annonc.2022.10.001&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr7-03946320251326699">
<span class="label">7.</span><cite>
Luoma AM, Suo S, Williams HL, et al.  (2020) Molecular pathways of colon inflammation induced by cancer immunotherapy. Cell
182: 655–671.e22.
</cite> [<a href="https://doi.org/10.1016/j.cell.2020.06.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7415717/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32603654/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=Molecular%20pathways%20of%20colon%20inflammation%20induced%20by%20cancer%20immunotherapy&amp;author=AM%20Luoma&amp;author=S%20Suo&amp;author=HL%20Williams&amp;volume=182&amp;publication_year=2020&amp;pages=655-671&amp;pmid=32603654&amp;doi=10.1016/j.cell.2020.06.001&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr8-03946320251326699">
<span class="label">8.</span><cite>
Li H, Fu ZY, Arslan ME, et al.  (2021) Differential diagnosis and management of immune checkpoint inhibitor-induced colitis: A comprehensive review. World Journal of Experimental Medicine
11: 79–92.
</cite> [<a href="https://doi.org/10.5493/wjem.v11.i6.79" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9553980/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36246150/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=World%20Journal%20of%20Experimental%20Medicine&amp;title=Differential%20diagnosis%20and%20management%20of%20immune%20checkpoint%20inhibitor-induced%20colitis:%20A%20comprehensive%20review&amp;author=H%20Li&amp;author=ZY%20Fu&amp;author=ME%20Arslan&amp;volume=11&amp;publication_year=2021&amp;pages=79-92&amp;pmid=36246150&amp;doi=10.5493/wjem.v11.i6.79&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr9-03946320251326699">
<span class="label">9.</span><cite>
Tang L, Wang J, Lin N, et al.  (2021) Immune checkpoint inhibitor-associated colitis: From mechanism to management. Frontiers in Immunology
12: 800879.
</cite> [<a href="https://doi.org/10.3389/fimmu.2021.800879" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8724248/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34992611/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Frontiers%20in%20Immunology&amp;title=Immune%20checkpoint%20inhibitor-associated%20colitis:%20From%20mechanism%20to%20management&amp;author=L%20Tang&amp;author=J%20Wang&amp;author=N%20Lin&amp;volume=12&amp;publication_year=2021&amp;pages=800879&amp;pmid=34992611&amp;doi=10.3389/fimmu.2021.800879&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr10-03946320251326699">
<span class="label">10.</span><cite>
Powell N, Ibraheim H, Raine T, et al.  (2020) British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis. The Lancet Gastroenterology and Hepatology
5: 679–697.
</cite> [<a href="https://doi.org/10.1016/S2468-1253(20)30014-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32553146/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=The%20Lancet%20Gastroenterology%20and%20Hepatology&amp;title=British%20Society%20of%20Gastroenterology%20endorsed%20guidance%20for%20the%20management%20of%20immune%20checkpoint%20inhibitor-induced%20enterocolitis&amp;author=N%20Powell&amp;author=H%20Ibraheim&amp;author=T%20Raine&amp;volume=5&amp;publication_year=2020&amp;pages=679-697&amp;pmid=32553146&amp;doi=10.1016/S2468-1253(20)30014-5&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr11-03946320251326699">
<span class="label">11.</span><cite>
Qin S, Xu L, Yi M, et al.  (2019) Novel immune checkpoint targets: Moving beyond PD-1 and CTLA-4. Molecular Cancer
18: 155.
</cite> [<a href="https://doi.org/10.1186/s12943-019-1091-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6833286/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31690319/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecular%20Cancer&amp;title=Novel%20immune%20checkpoint%20targets:%20Moving%20beyond%20PD-1%20and%20CTLA-4&amp;author=S%20Qin&amp;author=L%20Xu&amp;author=M%20Yi&amp;volume=18&amp;publication_year=2019&amp;pages=155&amp;pmid=31690319&amp;doi=10.1186/s12943-019-1091-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr12-03946320251326699">
<span class="label">12.</span><cite>
Hughes MS, Molina GE, Chen ST, et al.  (2019) Budesonide treatment for microscopic colitis from immune checkpoint inhibitors. The Journal for ImmunoTherapy of Cancer
7: 292.
</cite> [<a href="https://doi.org/10.1186/s40425-019-0756-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6839080/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31699151/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=The%20Journal%20for%20ImmunoTherapy%20of%20Cancer&amp;title=Budesonide%20treatment%20for%20microscopic%20colitis%20from%20immune%20checkpoint%20inhibitors&amp;author=MS%20Hughes&amp;author=GE%20Molina&amp;author=ST%20Chen&amp;volume=7&amp;publication_year=2019&amp;pages=292&amp;pmid=31699151&amp;doi=10.1186/s40425-019-0756-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr13-03946320251326699">
<span class="label">13.</span><cite>
Wang Y, Abu-Sbeih H, Mao E, et al.  (2018) Endoscopic and histologic features of immune checkpoint inhibitor related colitis. Inflammatory Bowel Disease
24: 1695–1705.</cite> [<a href="https://doi.org/10.1093/ibd/izy104" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29718308/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Inflammatory%20Bowel%20Disease&amp;title=Endoscopic%20and%20histologic%20features%20of%20immune%20checkpoint%20inhibitor%20related%20colitis&amp;author=Y%20Wang&amp;author=H%20Abu-Sbeih&amp;author=E%20Mao&amp;volume=24&amp;publication_year=2018&amp;pages=1695-1705&amp;pmid=29718308&amp;doi=10.1093/ibd/izy104&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr14-03946320251326699">
<span class="label">14.</span><cite>
Brahmer JR, Lacchetti C, Schneider BJ, et al.  (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. Journal of Clinical Oncology
36: 1714.
</cite> [<a href="https://doi.org/10.1200/JOP.18.00005" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29517954/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Clinical%20Oncology&amp;title=Management%20of%20immune-related%20adverse%20events%20in%20patients%20treated%20with%20immune%20checkpoint%20inhibitor%20therapy:%20American%20society%20of%20clinical%20oncology%20clinical%20practice%20guideline&amp;author=JR%20Brahmer&amp;author=C%20Lacchetti&amp;author=BJ%20Schneider&amp;volume=36&amp;publication_year=2018&amp;pages=1714&amp;pmid=29517954&amp;doi=10.1200/JOP.18.00005&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr15-03946320251326699">
<span class="label">15.</span><cite>
Beck TN, Kudinov AE, Dulaimi E, et al.  (2019) Case report: Reinitiating pembrolizumab treatment after small bowel perforation. BMC Cancer
19: 379.
</cite> [<a href="https://doi.org/10.1186/s12885-019-5577-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6482547/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31018834/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMC%20Cancer&amp;title=Case%20report:%20Reinitiating%20pembrolizumab%20treatment%20after%20small%20bowel%20perforation&amp;author=TN%20Beck&amp;author=AE%20Kudinov&amp;author=E%20Dulaimi&amp;volume=19&amp;publication_year=2019&amp;pages=379&amp;pmid=31018834&amp;doi=10.1186/s12885-019-5577-5&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr16-03946320251326699">
<span class="label">16.</span><cite>
Gougis P, Jochum F, Abbar B, et al.  (2024) Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade-a worldwide perspective. eClinicalMedicine Journal
70: 102536.</cite> [<a href="https://doi.org/10.1016/j.eclinm.2024.102536" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10981010/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38560659/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=eClinicalMedicine%20Journal&amp;title=Clinical%20spectrum%20and%20evolution%20of%20immune-checkpoint%20inhibitors%20toxicities%20over%20a%20decade-a%20worldwide%20perspective&amp;author=P%20Gougis&amp;author=F%20Jochum&amp;author=B%20Abbar&amp;volume=70&amp;publication_year=2024&amp;pages=102536&amp;pmid=38560659&amp;doi=10.1016/j.eclinm.2024.102536&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr17-03946320251326699">
<span class="label">17.</span><cite>
Cook S, Samuel V, Meyers DE, et al.  (2024) Immune-related adverse events and survival among patients with metastatic NSCLC treated with immune checkpoint inhibitors. JAMA Network Open
7(1): e2352302.</cite> [<a href="https://doi.org/10.1001/jamanetworkopen.2023.52302" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10797458/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38236598/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA%20Network%20Open&amp;title=Immune-related%20adverse%20events%20and%20survival%20among%20patients%20with%20metastatic%20NSCLC%20treated%20with%20immune%20checkpoint%20inhibitors&amp;author=S%20Cook&amp;author=V%20Samuel&amp;author=DE%20Meyers&amp;volume=7&amp;issue=1&amp;publication_year=2024&amp;pmid=38236598&amp;doi=10.1001/jamanetworkopen.2023.52302&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr18-03946320251326699">
<span class="label">18.</span><cite>
Wang DY, Salem JE, Cohen JV, et al.  (2018) Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis. JAMA Oncology
4(12): 1721–1728.
</cite> [<a href="https://doi.org/10.1001/jamaoncol.2018.3923" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6440712/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30242316/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA%20Oncology&amp;title=Fatal%20toxic%20effects%20associated%20with%20immune%20checkpoint%20inhibitors:%20A%20systematic%20review%20and%20meta-analysis&amp;author=DY%20Wang&amp;author=JE%20Salem&amp;author=JV%20Cohen&amp;volume=4&amp;issue=12&amp;publication_year=2018&amp;pages=1721-1728&amp;pmid=30242316&amp;doi=10.1001/jamaoncol.2018.3923&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr19-03946320251326699">
<span class="label">19.</span><cite>
Rabbani SA, Khurana A, El-Tanani M, et al.  (2024) Gastrointestinal adverse events associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the EudraVigilance and VigiAccess databases. Expert Opinion on Drug Safety
11: 1–11.</cite> [<a href="https://doi.org/10.1080/14740338.2024.2416539" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39392233/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Expert%20Opinion%20on%20Drug%20Safety&amp;title=Gastrointestinal%20adverse%20events%20associated%20with%20immune%20checkpoint%20inhibitors:%20a%20pharmacovigilance%20analysis%20of%20the%20EudraVigilance%20and%20VigiAccess%20databases&amp;author=SA%20Rabbani&amp;author=A%20Khurana&amp;author=M%20El-Tanani&amp;volume=11&amp;publication_year=2024&amp;pages=1-11&amp;pmid=39392233&amp;doi=10.1080/14740338.2024.2416539&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr20-03946320251326699">
<span class="label">20.</span><cite>
Haanen J, Jordan K, Longo F, et al. (2017) Patient guide on immunotherapy-related side effects and their management
<a href="https://www.esmo.org/for-patients/patient-guides/patient-guide-on-immunotherapy-related-side-effects-and-their-management" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.esmo.org/for-patients/patient-guides/patient-guide-on-immunotherapy-related-side-effects-and-their-management</a></cite>
</li>
<li id="bibr21-03946320251326699">
<span class="label">21.</span><cite>
Pollack MH, Betof A, Dearden H, et al.  (2018) Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Annals of Oncology
29: 250–255.
</cite> [<a href="https://doi.org/10.1093/annonc/mdx642" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5834131/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29045547/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Annals%20of%20Oncology&amp;title=Safety%20of%20resuming%20anti-PD-1%20in%20patients%20with%20immune-related%20adverse%20events%20(irAEs)%20during%20combined%20anti-CTLA-4%20and%20anti-PD1%20in%20metastatic%20melanoma&amp;author=MH%20Pollack&amp;author=A%20Betof&amp;author=H%20Dearden&amp;volume=29&amp;publication_year=2018&amp;pages=250-255&amp;pmid=29045547&amp;doi=10.1093/annonc/mdx642&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr22-03946320251326699">
<span class="label">22.</span><cite>
Gobbini E, Toffart AC, Perol M, et al.  (2020) Immune checkpoint inhibitors rechallenge efficacy in non-small-cell lung cancer patients. Clinical Lung Cancer
21: E497–510.</cite> [<a href="https://doi.org/10.1016/j.cllc.2020.04.013" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32605892/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clinical%20Lung%20Cancer&amp;title=Immune%20checkpoint%20inhibitors%20rechallenge%20efficacy%20in%20non-small-cell%20lung%20cancer%20patients&amp;author=E%20Gobbini&amp;author=AC%20Toffart&amp;author=M%20Perol&amp;volume=21&amp;publication_year=2020&amp;pmid=32605892&amp;doi=10.1016/j.cllc.2020.04.013&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr23-03946320251326699">
<span class="label">23.</span><cite>
Abu-Sbeih H, Ali FS, Naqash AR, et al.  (2019) Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis. Journal of Clinical Oncology
37: 2738–45.</cite> [<a href="https://doi.org/10.1200/JCO.19.00320" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6800279/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31163011/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Clinical%20Oncology&amp;title=Resumption%20of%20immune%20checkpoint%20inhibitor%20therapy%20after%20immune-mediated%20colitis&amp;author=H%20Abu-Sbeih&amp;author=FS%20Ali&amp;author=AR%20Naqash&amp;volume=37&amp;publication_year=2019&amp;pmid=31163011&amp;doi=10.1200/JCO.19.00320&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr24-03946320251326699">
<span class="label">24.</span><cite>
Abu-Sbeih H, Ali FS, Wang X, et al.  (2019) Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. The Journal for ImmunoTherapy of Cancer
7: 93.
</cite> [<a href="https://doi.org/10.1186/s40425-019-0577-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6444537/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30940209/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=The%20Journal%20for%20ImmunoTherapy%20of%20Cancer&amp;title=Early%20introduction%20of%20selective%20immunosuppressive%20therapy%20associated%20with%20favorable%20clinical%20outcomes%20in%20patients%20with%20immune%20checkpoint%20inhibitor-induced%20colitis&amp;author=H%20Abu-Sbeih&amp;author=FS%20Ali&amp;author=X%20Wang&amp;volume=7&amp;publication_year=2019&amp;pages=93&amp;pmid=30940209&amp;doi=10.1186/s40425-019-0577-1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr25-03946320251326699">
<span class="label">25.</span><cite>
Sivan A, Corrales L, Hubert N, et al.  (2015) Commensal bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science
350: 1084–1049.</cite> [<a href="https://doi.org/10.1126/science.aac4255" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4873287/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26541606/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Commensal%20bifidobacterium%20promotes%20antitumor%20immunity%20and%20facilitates%20anti-PD-L1%20efficacy&amp;author=A%20Sivan&amp;author=L%20Corrales&amp;author=N%20Hubert&amp;volume=350&amp;publication_year=2015&amp;pmid=26541606&amp;doi=10.1126/science.aac4255&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr26-03946320251326699">
<span class="label">26.</span><cite>
Hashash JG, Francis FF, Farraye FA. (2021) Diagnosis and management of immune checkpoint inhibitor colitis. Gastroenterology &amp; Hepatology
17: 358–366.
</cite> [<a href="/articles/PMC8475264/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34602898/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Gastroenterology%20&amp;%20Hepatology&amp;title=Diagnosis%20and%20management%20of%20immune%20checkpoint%20inhibitor%20colitis&amp;author=JG%20Hashash&amp;author=FF%20Francis&amp;author=FA%20Farraye&amp;volume=17&amp;publication_year=2021&amp;pages=358-366&amp;pmid=34602898&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from International Journal of Immunopathology and Pharmacology are provided here courtesy of <strong>SAGE Publications</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1177/03946320251326699"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/10.1177_03946320251326699.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (1.8 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12033556/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12033556/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12033556%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12033556/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12033556/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12033556/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40231646/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12033556/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40231646/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12033556/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12033556/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="kLv17WUNgca3lz8AeSquGck0LV4ADCIP4AQABZ2n3YdUHH8RS4vrDO46Hipfc6Fc">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Web Policies

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    FOIA

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    HHS Vulnerability Disclosure

    
</a>

                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Help

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Accessibility

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Careers

    
</a>

                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    NLM

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    NIH

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    HHS

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    USA.gov

    
</a>

                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-370d5dd6.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-917ba005.js"></script>
    
    

    </body>
</html>
